PXD041324 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | New ruthenium-cyclopentadienyl complexes affect colorectal cancer hallmarks showing high therapeutic potential |
Description | Colorectal cancer (CRC) is one of the most lethal cancers worldwide. Current therapeutic strategies are accompanied by low success rates and several side effects, representing a relevant clinical problem and requiring the discovery of new and more effective therapeutic alternatives. Ruthenium drugs emerged as one of the most promising metallodrugs due to their high selectivity to cancer cells. In this work, we studied for the first time the anticancer properties and mechanisms of action of four lead Ru-cyclopentadienyl compounds, namely PMC79, PMC78, LCR134 and LCR220, in CRC-derived cell lines. Biological assays were performed in CRC cell lines to evaluate cellular distribution, colony formation, cell cycle, proliferation, apoptosis, motility as well as cytoskeleton and mitochondrial alterations. Our results showed that all compounds displayed high bioactivity and selectivity, as shown by low IC50 concentrations against CRC cells. We observed that all Ru compounds had different intracellular distributions and inhibited to a high extent the clonogenic ability and proliferation of CRC cells. In addition, PMC79, LCR134 and LCR220 induced apoptosis, increased the levels of reactive oxygen species, induced mitochondrial alterations and affected F-actin cytoskeleton organization and cellular motility. A proteomic analysis showed that these compounds induce alterations in several cellular proteins related to the phenotypic alterations induced. Overall, we demonstrated that Ru compounds, in special PMC79 and LCR220, present promising anticancer activity in CRC cells and potential to be used as new metallodrugs for CRC therapy. |
HostingRepository | PRIDE |
AnnounceDate | 2023-11-14 |
AnnouncementXML | Submission_2023-11-14_09:03:53.400.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Eduard Sabidó |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue |
Instrument | Orbitrap Fusion Lumos |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2023-04-04 04:37:52 | ID requested | |
1 | 2023-07-20 12:32:02 | announced | |
⏵ 2 | 2023-11-14 09:03:55 | announced | 2023-11-14: Updated project metadata. |
Publication List
Br, á, s AR, Fernandes P, Moreira T, Morales-Sanfrutos J, Sabid, ó E, Antunes AMM, Valente A, Preto A, New Ruthenium-Cyclopentadienyl Complexes Affect Colorectal Cancer Hallmarks Showing High Therapeutic Potential. Pharmaceutics, 15(6):(2023) [pubmed] |
Keyword List
submitter keyword: ruthenium-cyclopentadienyl compounds |
colorectal cancer |
active targeting |
passive targeting |
Contact List
Eduard Sabidó |
contact affiliation | Center for Genomic Regulation, Universitat Pompeu Fabra |
contact email | eduard.sabido@crg.eu |
lab head | |
Eduard Sabidó |
contact affiliation | Centre de Regulació Genòmica |
contact email | eduard.sabido@crg.cat |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/07/PXD041324 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD041324
- Label: PRIDE project
- Name: New ruthenium-cyclopentadienyl complexes affect colorectal cancer hallmarks showing high therapeutic potential